Bordetella pertussis and vaccination: The persistence of a genetically monomorphic pathogen

Infection, Genetics and Evolution

Volumn 10, Issue 1, 2010, Pages 36-49

  Mooi, Frits R ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Adaptation; Bordetella pertussis; Evolution; Resurgence; Vaccine; Whooping cough

Indexed keywords

PERTUSSIS TOXIN; PERTUSSIS VACCINE;

ANTIGENIC VARIATION; BACTERIAL GENOME; BACTERIAL IMMUNITY; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; BORDETELLA PERTUSSIS; EVOLUTIONARY ADAPTATION; GENE FREQUENCY; GENE INSERTION SEQUENCE; GENETIC IMMUNIZATION; GENETIC VARIABILITY; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; PERTUSSIS; PHYLOGENETIC TREE; PRIORITY JOURNAL; REVIEW; SHORT TANDEM REPEAT; SINGLE NUCLEOTIDE POLYMORPHISM; VACCINE PRODUCTION;

ADAPTATION, PHYSIOLOGICAL; ADOLESCENT; ADULT; BORDETELLA PERTUSSIS; COMMUNICABLE DISEASES, EMERGING; HUMANS; PERTUSSIS VACCINE; POLYMORPHISM, SINGLE NUCLEOTIDE; VACCINATION; WHOOPING COUGH;

BORDETELLA PERTUSSIS;

EID: 72149093505     PISSN: 15671348     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.meegid.2009.10.007     Document Type: Review

References (173)

1. Advani A., Donnelly D., Gustafsson L., and Hallander H.O. Changes of the Swedish Bordetella pertussis population in incidence peaks during an acellular pertussis vaccine period between 1997 and 2004. APMIS 115 (2007) 299-310
2. Advani A., Gustafsson L., Carlsson R.M., Donnelly D., and Hallander H.O. Clinical outcome of pertussis in Sweden: association with pulsed-field gel electrophoresis profiles and serotype. APMIS 115 (2007) 736-742
3. Advani A., van der Heide H.G.J., Hallander H., and Mooi F.R. Analysis of Bordetella pertussis isolates with three typing methods: characterization of an epidemic lineage. J. Microb. Meth. 78 (2009) 297-301
4. Anonymous. Vaccination against whooping-cough; relation between protection in children and results of laboratory tests; a report to the Whooping-cough Immunization Committee of the Medical Research Council and to the medical officers of health for Cardiff, Leeds, Leyton, Manchester, Middlesex, Oxford, Poole, Tottenham, Walthamstow, and Wembley. Br. Med. J. 2 (1956) 454-462
5. Ausiello C.M., Urbani F., la Sala A., Lande R., and Cassone A. Vaccine- and antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines. Infect. Immun. 65 (1997) 2168-2174
6. Bartoloni A., Pizza M., Bigio M., Nucci D., Ashworth L.A., Irons L.I., Robinson A., Burns D., Manclark C., Sato H., and Rappuoli R. Mapping of a protective epitope of pertussis toxin by in vitro refolding of recombinant fragments. Bio/Technology 6 (1988) 709-712
7. Berbers G.A., de Greeff S.C., and Mooi F.R. Improving pertussis vaccination. Hum. Vacc. 5 (2009) 38-44
8. Borisova O., Kombarova S.Y., Zakharova N.S., van Gent M., Aleshkin V.A., Mazurova I., and Mooi F.R. Antigenic divergence between Bordetella pertussis clinical isolates from Moscow, Russia, and vaccine strains. Clin. Vacc. Immunol. 14 (2007) 234-238
9. Bottero D., Gaillard M.E., Fingermann M., Weltman G., Fernandez J., Sisti F., Graieb A., Roberts R., Rico O., Rios G., Regueira M., Binsztein N., and Hozbor D. Pulse field gel electrophoresis, pertactin, pertussis toxin S1 subunit polymorphisms and surfaceome analysis of vaccine and clinical Bordetella pertussis strains. Clin. Vacc. Immunol. 14 (2007) 1490-1498
10. Bouchez V., Brun D., Cantinelli T., Dore G., Njamkepo E., and Guiso N. First report and detailed characterization of B. pertussis isolates not expressing pertussis toxin or pertactin. Vaccine (2009) (online)
11. Byrne S., and Slack A.T. Analysis of Bordetella pertussis pertactin and pertussis toxin types from Queensland, Australia, 1999-2003. BMC Infect. Dis. 6 (2006) 53
12. Brinig M.M., Cummings C.A., Sanden G.N., Stefanelli P., Lawrence A., et al. Significant gene order and expression differences in Bordetella pertussis despite limited gene content variation. J. Bacteriol. 188 (2006) 2375-2382
13. Carbonetti N.H. Immunomodulation in the pathogenesis of Bordetella pertussis infection and disease. Curr. Opin. Pharmacol. 7 (2007) 272-278
14. Caro V., Bouchez V., Guiso N., Gatti B., Agosti M.R., and Ayala S.E. Pertussis in Argentina and France. Vaccine 25 (2007) 4335-4339
15. Caro V., Hot D., Guigon G., Hubans C., Arrive M., Soubigou G., Renauld-Mongenie G., Antoine R., Locht C., Lemoine Y., and Guiso N. Temporal analysis of French Bordetella pertussis isolates by comparative whole-genome hybridization. Microb. Infect. 8 (2006) 2228-2235
16. Caro V., Njamkepo E., van Amersfoorth S.C., Mooi F.R., Advani A., Hallander H.O., He Q., Mertsola J., Riffelmann M., Vahrenholz C., vonKonig C.H.W., and Guiso N. Pulsed-field gel electrophoresis analysis of Bordetella pertussis populations in various European countries with different vaccine policies. Microb. Infect. 7 (2005) 976-982
17. Carroll S.B. Evo-devo and an expanding evolutionary synthesis: a genetic theory of morphological evolution. Cell 134 (2008) 25-36
18. Cassiday P., Sanden G., Heuvelman K., Mooi F., Bisgard K.M., and Popovic T. Polymorphism in Bordetella pertussis pertactin and pertussis toxin virulence factors in the United States, 1935-1999. J. Infect. Dis. 182 (2000) 1402-1408
19. Charles I.G., Li J.L., Roberts M., Beesley K., Romanos M., Pickard D.J., Francis M., Campbell D., Dougan G., Brennan M.J., Manclark C.R., Jensen M.A., Heron I., Chubb A., Novotny P., and Fairweather N.F. Identification and characterization of a protective immunodominant B cell epitope of pertactin (P.69) from Bordetella pertussis. Eur. J. Immunol. 21 (1991) 1147-1153
20. Cherry J.D., Gornbein J., Heininger U., and Stehr K. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 16 (1998) 1901-1906
21. Cornelius C.A., Quenee L.E., Elli D., Ciletti N.A., and Schneewind O. Yersinia pestis IS1541 transposition provides for escape from plague immunity. Infect. Immun. 77 (2009) 1807-1816
22. Cromer B.A., Goydos J., Hackell J., Mezzatesta J., Dekker C., and Mortimer E.A. Unrecognized pertussis infection in adolescents. Am. J. Dis. Child. 147 (1993) 575-577
23. Cummings C.A., Brinig M.M., Lepp P.W., van de Pas S., and Relman D.A. Bordetella species are distinguished by patterns of substantial gene loss and host adaptation. J. Bacteriol. 186 (2004) 1484-1492
24. Cummings C.A., Bootsma H.J., Relman D.A., and Miller J.F. Species- and strain-specific control of a complex, flexible regulon by Bordetella BvgAS. J. Bacteriol. 188 (2006) 1775-1785
25. Curry S.R., Marsh J.W., Muto C.A., O'Leary M.M., Pasculle A.W., and Harrison L.H. tcdC genotypes associated with severe TcdC truncation in an epidemic clone and other strains of Clostridium difficile. J. Clin. Microbiol. 45 (2007) 215-221
26. Dalet K., Weber C., Guillemot L., Njamkepo E., and Guiso N. Characterization of adenylate cyclase-hemolysin gene duplication in a Bordetella pertussis isolate. Infect. Immun. 72 (2004) 4874-4877
27. David S., van Furth R., and Mooi F.R. Efficacies of whole cell and acellular pertussis vaccines against Bordetella parapertussis in a mouse model. Vaccine 22 (2004) 1892-1898
28. Davison F., and Nair V. Use of Marek's disease vaccines: could they be driving the virus to increasing virulence?. Expert Rev. Vacc. 4 (2005) 77-88
29. Deen J.L., Mink C.A., Cherry J.D., Christenson P.D., Pineda E.F., Lewis K., Blumberg D.A., and Ross L.A. Household contact study of Bordetella pertussis infections. Clin. Infect. Dis. 21 (1995) 1211-1219
30. de Greeff S.C., Mooi F.R., Schellekens J.F., and de Melker H.E. Impact of acellular pertussis preschool booster vaccination on disease burden of pertussis in The Netherlands. Pediatr. Infect. Dis. J. 27 (2008) 218-223
31. De Magistris M.T., Di Tommaso A., Domenighini M., Censini S., Tagliabue A., Oksenberg J.R., Steinman L., Judd A.K., O'Sullivan D., and Rappuoli R. Interaction of the pertussis toxin peptide containing residues 30-42 with DR1 and the T-cell receptors of 12 human T-cell clones. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 2990-2994
32. De Magistris M.T., Rappuoli R., and Tagliabue A. Human T cell immunity against Bordetella pertussis analyzed at clonal level. Ann. Ist Super. Sanita 27 (1991) 33-36
33. De Magistris M.T., Romano M., Bartoloni A., Rappuoli R., and Tagliabue A. Human T cell clones define S1 subunit as the most immunogenic moiety of pertussis toxin and determine its epitope map. J. Exp. Med. 169 (1989) 1519-1532
34. de Melker H.E., Versteegh F.G., Schellekens J.F., Teunis P.F., and Kretzschmar M. The incidence of Bordetella pertussis infections estimated in the population from a combination of serological surveys. J. Infect. 53 (2006) 106-113
35. De Schutter I., Malfroot A., Dab I., Hoebrekx N., Muyldermans G., Pierard D., and Lauwers S. Molecular typing of Bordetella pertussis isolates recovered from Belgian children and their household members. Clin. Infect. Dis. 36 (2003) 1391-1396
36. Diavatopoulos D.A., Cummings C.A., Schouls L.M., Brinig M.M., Relman D.A., and Mooi F.R. Bordetella pertussis, the causative agent of whooping cough, evolved from a distinct, human-associated lineage of B. bronchiseptica. PLoS Pathog. 1 (2005) 373-383
37. Diavatopoulos D.A., Cummings C.A., van der Heide H.G., van Gent M., Liew S., Relman D.A., and Mooi F.R. Characterization of a highly conserved island in the otherwise divergent Bordetella holmesii and Bordetella pertussis genomes. J. Bacteriol. 188 (2006) 8385-8394
38. Di Tommaso A., De Magistris M.T., Bugnoli M., Marsili I., Rappuoli R., and Abrignani S. Formaldehyde treatment of proteins can constrain presentation to T cells by limiting antigen processing. Infect. Immun. 62 (1994) 1830-1834
39. Edwards K.M., Decker M.D., Plotkin S.A., and Orenstein W.A. Pertussis vaccine. Vaccines (2004), Saunders pp. 471-528
40. Edwards K.M., Meade B.D., Decker M.D., Reed G.F., Rennels M.B., Steinhoff M.C., Anderson E.L., Englund J.A., Pichichero M.E., and Deloria M.A. Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics 96 (1995) 548-557
41. Electronic, 2009. http://www.hpa.org.uk/infections/topics_az/whoopingcough/data_not_death.htm.
42. Elomaa A., Advani A., Donnelly D., Antila M., Mertsola J., Hallander H., and He Q. Strain variation among Bordetella pertussis isolates in Finland, where the whole-cell pertussis vaccine has been used for 50 years. J. Clin. Microbiol. 43 (2005) 3681-3687
43. Elomaa A., Advani A., Donnelly D., Antila M., Mertsola J., He Q., and Hallander H. Population dynamics of Bordetella pertussis in Finland and Sweden, neighbouring countries with different vaccination histories. Vaccine 25 (2007) 918-926
44. Ewald P.W. Evolution of Infectious Diseases (1994), Oxford University Press, Oxford
45. Fazekas d.S.G., and Webster R.G. Disquisitions of original antigenic sin. I. Evidence in man. J. Exp. Med. 124 (1966) 331-345
46. Fingermann M., Fernandez J., Sisti F., Rodriguez M.E., Gatti B., Bottero D., Graieb A., Gaillard M.E., Ayala S.G., Mooi F.R., Lopardo H., and Hozbor D. Differences of circulating Bordetella pertussis population in Argentina from the strain used in vaccine production. Vaccine 24 (2006) 3513-3521
47. Frank S.A., and Schmid-Hempel P. Mechanisms of pathogenesis and the evolution of parasite virulence. J. Evol. Biol. 21 (2008) 396-404
48. Fry N.K., Neal S., Harrison T.G., Miller E., Matthews R., and George R.C. Genotypic variation in the Bordetella pertussis virulence factors pertactin and pertussis toxin in historical and recent clinical isolates in the United Kingdom. Infect. Immun. 69 (2001) 5520-5528
49. Gandon S., and Day T. Evidences of parasite evolution after vaccination. Vaccine 26 Suppl. 3 (2008) C4-C7
50. Gandon S., Mackinnon M.J., Nee S., and Read A.F. Imperfect vaccines and the evolution of pathogen virulence. Nature 414 (2001) 751-756
51. Geuijen C.A., Willems R.J., Bongaerts M., Top J., Gielen H., and Mooi F.R. Role of the Bordetella pertussis minor fimbrial subunit, FimD, in colonization of the mouse respiratory tract. Infect. Immun. 65 (1997) 4222-4228
52. Geuijen C.A., Willems R.J., Hoogerhout P., Puijk W.C., Meloen R.H., and Mooi F.R. Identification and characterization of heparin binding regions of the Fim2 subunit of Bordetella pertussis. Infect. Immun. 66 (1998) 2256-2263
53. Geuijen C.A., Willems R.J., and Mooi F.R. The major fimbrial subunit of Bordetella pertussis binds to sulfated sugars. Infect. Immun. 64 (1996) 2657-2665
54. Gogol E.B., Cummings C.A., Burns R.C., and Relman D.A. Phase variation and microevolution at homopolymeric tracts in Bordetella pertussis. BMC Genom. 8 (2007) 122
55. Goodnow R.A. Biology of Bordetella bronchiseptica. Microbiol. Rev. 44 (1980) 722-738
56. Granstrom M., and Granstrom G. Serological correlates in whooping cough. Vaccine 11 (1993) 445-448
57. Greenberg D.P., vonKonig C.H.W., and Heininger U. Health burden of pertussis in infants and children. Pediatr. Infect. Dis. J. 24 (2005) S39-S43
58. Guiso N., Boursaux-Eude C., Weber C., Hausman S.Z., Sato H., Iwaki M., Kamachi K., Konda T., and Burns D.L. Analysis of Bordetella pertussis isolates collected in Japan before and after introduction of acellular pertussis vaccines. Vaccine 19 (2001) 3248-3252
59. Gzyl A., Augustynowicz E., Gniadek G., Rabczenko D., Dulny G., and Slusarczyk J. Sequence variation in pertussis S1 subunit toxin and pertussis genes in Bordetella pertussis strains used for the whole-cell pertussis vaccine produced in Poland since 1960: efficiency of the DTwP vaccine-induced immunity against currently circulating B. pertussis isolates. Vaccine 22 (2004) 2122-2128
60. Gzyl A., Augustynowicz E., van Loo I., and Slusarczyk J. Temporal nucleotide changes in pertactin and pertussis toxin genes in Bordetella pertussis strains isolated from clinical cases in Poland. Vaccine 20 (2001) 299-303
61. Hallander H., Advani A., Riffelmann M., vonKonig C.H.W., Caro V., Guiso N., Mooi F.R., Gzyl A., Kaltoft M.S., Fry N.K., Mertsola J., and He Q. Bordetella pertussis strains circulating in Europe in 1999 to 2004 as determined by pulsed-field gel electrophoresis. J. Clin. Microbiol. 45 (2007) 3257-3262
62. Hallander H.O., Advani A., Donnelly D., Gustafsson L., and Carlsson R.M. Shifts of Bordetella pertussis variants in Sweden from 1970 to 2003, during three periods marked by different vaccination programs. J. Clin. Microbiol. 43 (2005) 2856-2865
63. Hallander H.O., Gustafsson L., Ljungman M., and Storsaeter J. Pertussis antitoxin decay after vaccination with DTPa. Response to a first booster dose 3 1/2-6 1/2 years after the third vaccine dose. Vaccine 23 (2005) 5359-5364
64. Halperin S.A. The control of pertussis - 2007 and beyond. N. Engl. J. Med. 356 (2007) 110-113
65. Han H.J., Kamachi K., Okada K., Toyoizumi-Ajisaka H., Sasaki Y., and Arakawa Y. Antigenic variation in Bordetella pertussis isolates recovered from adults and children in Japan. Vaccine 26 (2008) 1530-1534
66. Hardwick T.H., Cassiday P., Weyant R.S., Bisgard K.M., and Sanden G.N. Changes in predominance and diversity of genomic subtypes of Bordetella pertussis isolated in the United States, 1935 to 1999. Emerg. Infect. Dis. 8 (2002) 44-49
67. Hausman S.Z., and Burns D.L. Use of pertussis toxin encoded by ptx genes from Bordetella bronchiseptica to model the effects of antigenic drift of pertussis toxin on antibody neutralization. Infect. Immun. 68 (2000) 3763-3767
68. Hazenbos W.L., Geuijen C.A., van den Berg B.M., Mooi F.R., and van Furth R. Bordetella pertussis fimbriae bind to human monocytes via the minor fimbrial subunit FimD. J. Infect. Dis. 171 (1995) 924-929
69. Hazenbos W.L., van den Berg B.M., Geuijen C.W., Mooi F.R., and van Furth R. Binding of FimD on Bordetella pertussis to very late antigen-5 on monocytes activates complement receptor type 3 via protein tyrosine kinases. J. Immunol. 155 (1995) 3972-3978
70. He Q., and Mertsola J. Factors contributing to pertussis resurgence. Future Microbiol. 3 (2008) 329-339
71. Heikkinen E., Kallonen T., Saarinen L., Sara R., King A.J., Mooi F.R., Soini J.T., Mertsola J., and He Q. Comparative genomics of Bordetella pertussis reveals progressive gene loss in Finnish strains. PLoS ONE 2 (2007) e904
72. Hewlett E.L. Acellular pertussis trial. Pediatrics 98 (1996) 800
73. Hijnen M., de Voer R., Mooi F.R., Schepp R., Moret E.E., van Gageldonk P., Smits G., and Berbers G.A. The role of peptide loops of the Bordetella pertussis protein P.69 pertactin in antibody recognition. Vaccine 25 (2007) 5902-5914
74. Hodder S.L., Cherry J.D., Mortimer Jr. E.A., Ford A.B., Gornbein J., and Papp K. Antibody responses to Bordetella pertussis antigens and clinical correlations in elderly community residents. Clin. Infect. Dis. 31 (2000) 7-14
75. Holmes R.K. Biology and molecular epidemiology of diphtheria toxin and the tox gene. J. Infect. Dis. 181 Suppl. 1 (2000) S156-S167
76. Hozbor, D., Mooi, F., Flores, D., Weltman, G., Bottero, D., Fossati, S., Lara, C., Gaillard, M.E., Pianciola, L., Zurita, E., Fioriti, A., Archuby, D., Galas, M., Binsztein, N., Regueira, M., Castuma, C., Fingermann, M., Graieb, A., 2009. Pertussis epidemiology in Argentina trends over 2004-2007. J. Infect. (online).
77. Iwata S., Aoyama T., Goto A., Iwai H., Sato Y., Akita H., Murase Y., Oikawa T., Iwata T., and Kusano S. Mixed outbreak of Bordetella pertussis and Bordetella parapertussis in an apartment house. Dev. Biol. Stand. 73 (1991) 333-341
78. Jacob-Dubuisson F., and Locht C. The Bordetella adhesins. In: Locht C. (Ed). Bordetella Molecular Microbiology (2007), Horizon Bioscience, Norfolk, UK 69-96
79. King A.J., Berbers G., van Oirschot H.F., Hoogerhout P., Knipping K., and Mooi F.R. Role of the polymorphic region 1 of the Bordetella pertussis protein pertactin in immunity. Microbiology 147 (2001) 2885-2895
80. King A.J., van Gorkom T., Pennings J.L., van der Heide H.G., He Q., Diavatopoulos D., Heuvelman K., van Gent M., van Leeuwen K., and Mooi F.R. Comparative genomic profiling of Dutch clinical Bordetella pertussis isolates using DNA microarrays: identification of genes absent from epidemic strains. BMC Genom. 9 (2008) 311
81. Kirimanjeswara G.S., Agosto L.M., Kennett M.J., Bjornstad O.N., and Harvill E.T. Pertussis toxin inhibits neutrophil recruitment to delay antibody-mediated clearance of Bordetella pertussis. J. Clin. Invest. 115 (2005) 3594-3601
82. Kodama A., Kamachi K., Horiuchi Y., Konda T., and Arakawa Y. Antigenic divergence suggested by correlation between antigenic variation and pulsed-field gel electrophoresis profiles of Bordetella pertussis isolates in Japan. J. Clin. Microbiol. 42 (2004) 5453-5457
83. Kolodkina V.L., Titov L.P., Sharapa T.N., and Drozhzhina O.N. Point mutations in tox promoter/operator and diphtheria toxin repressor (DTXR) gene associated with the level of toxin production by Corynebacterium diphtheriae strains isolated in Belarus. Mol. Gen. Mikrobiol. Virusol. 1 (2007) 22-29
84. Kourova N., Caro V., Weber C., Thiberge S., Chuprinina R., Tseneva G., and Guiso N. Comparison of the Bordetella pertussis and Bordetella parapertussis isolates circulating in Saint Petersburg between 1998 and 2000 with Russian vaccine strains. J. Clin. Microbiol. 41 (2003) 3706-3711
85. Lapin J.H. Whooping Cough (1943), Charles C. Thomas, Springfield, Illinois
86. Lawrence J.G. Common themes in the genome strategies of pathogens. Curr. Opin. Genet. Dev. 15 (2005) 584-588
87. Lederberg J. Infectious history. Science 288 (2000) 287-293
88. Lee Y.S., Yang C.Y., Lu C.H., and Tseng Y.H. Molecular epidemiology of Bordetella pertussis isolated in Taiwan, 1992-1997. Microbiol. Immunol. 47 (2003) 903-909
89. Leininger E., Ewanowich C.A., Bhargava A., Peppler M.S., Kenimer J.G., and Brennan M.J. Comparative roles of the Arg-Gly-Asp sequence present in the Bordetella pertussis adhesins pertactin and filamentous hemagglutinin. Infect. Immun. 60 (1992) 2380-2385
90. Leininger E., Roberts M., Kenimer J.G., Charles I.G., Fairweather N., Novotny P., and Brennan M.J. Pertactin, an Arg-Gly-Asp-containing Bordetella pertussis surface protein that promotes adherence of mammalian cells. Proc. Natl. Acad. Sci. U.S.A. 88 (1991) 345-349
91. Li M., Diep B.A., Villaruz A.E., Braughton K.R., Jiang X., DeLeo F.R., Chambers H.F., Lu Y., and Otto M. Evolution of virulence in epidemic community-associated methicillin-resistant Staphylococcus aureus. Proc. Natl. Acad. Sci. U.S.A. 106 (2009) 5883-5888
92. Lipsitch M., and O'Hagan J.J. Patterns of antigenic diversity and the mechanisms that maintain them. J. R. Soc. Interface 4 (2007) 787-802
93. Litt D.J., Neal S.E., and Fry N.K. Changes in genetic diversity of the UK Bordetella pertussis population between 1920 and 2006 reflect vaccination coverage and the emergence of a single dominant clonal type. J. Clin. Microbiol. 47 (2009) 680-688
94. Luttinger P. The epidemiology of pertussis. Am. J. Dis. Child. 12 (1916) 290-315
95. Mackinnon M.J., and Read A.F. Immunity promotes virulence evolution in a malaria model. PLoS Biol. 2 (2004) E230
96. Magner L.N. In: Kiple K.F. (Ed). The Cambridge World History of Human Disease (1993) 392-400
97. Maharjan R.P., Gu C., Reeves P.R., Sintchenko V., Gilbert G.L., and Lan R. Genome-wide analysis of single nucleotide polymorphisms in Bordetella pertussis using comparative genomic sequencing. Res. Microbiol. 159 (2008) 602-608
98. Makinen J., Mertsola J., Mooi F.R., Van Amersfoorth S., Arvilommi H., Viljanen M.K., and He Q. Bordetella pertussis isolates, Finland. Emerg. Infect. Dis. 11 (2005) 183-184
99. Makinen J., Mertsola J., Soini H., Arvilommi H., Viljanen M.K., Guiso N., and He Q. PFGE and pertactin gene sequencing suggest limited genetic variability within the Finnish Bordetella parapertussis population. J. Med. Microbiol. 52 (2003) 1059-1063
100. Mascart F., Hainaut M., Peltier A., Verscheure V., Levy J., and Locht C. Modulation of the infant immune responses by the first pertussis vaccine administrations. Vaccine 25 (2007) 391-398
101. Mastrantonio P., Spigaglia P., van Oirschot H., van der Heide H.G., Heuvelman K., Stefanelli P., and Mooi F.R. Antigenic variants in Bordetella pertussis strains isolated from vaccinated and unvaccinated children. Microbiology 145 Pt 8 (1999) 2069-2075
102. Maurelli A.T., Fernandez R.E., Bloch C.A., Rode C.K., and Fasano A. "Black holes" and bacterial pathogenicity: a large genomic deletion that enhances the virulence of Shigella spp. and enteroinvasive Escherichia coli. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 3943-3948
103. Mazurova I.K., Borisova O.I., Kombarova S.I., Zakharova N.S., and Aleshkin V.A. Molecular genetic characteristics of the B. pertussis strains isolated in different periods of the pertussis epidemic process. J. Mol. Gen. Microb. Virol. (Moscow, Russia) 4 (2005) 21-25
104. McDonald L.C., Killgore G.E., Thompson A., Owens Jr. R.C., Kazakova S.V., Sambol S.P., Johnson S., and Gerding D.N. An epidemic, toxin gene-variant strain of Clostridium difficile. N. Engl. J. Med. 353 (2005) 2433-2441
105. McIntyre P., and Wood N. Pertussis in early infancy: disease burden and preventive strategies. Curr. Opin. Infect. Dis. 22 (2009) 215-223
106. Mertsola J. Mixed outbreak of Bordetella pertussis and Bordetella parapertussis infection in Finland. Eur. J. Clin. Microbiol. 4 (1985) 123-128
107. Mielcarek N., Riveau G., Remoue F., Antoine R., Capron A., and Locht C. Homologous and heterologous protection after single intranasal administration of live attenuated recombinant Bordetella pertussis. Nat. Biotechnol. 16 (1998) 454-457
108. Miller E., Vurdien J.E., and White J.M. The epidemiology of pertussis in England and Wales. Commun. Dis. Rep. CDR Rev. 2 (1992) R152-R154
109. Miller J.J., Silverberg R.J., Saito T.M., and Umber J.B. An agglutinative reaction for Hemophilus pertussis. II. Its relation to clinical immunity. J. Pediatr. 22 (1943) 644-651
110. Mira A., Pushker R., and Rodriguez-Valera F. The neolithic revolution of bacterial genomes. Trends Microbiol. 14 (2006) 200-206
111. Mooi F.R., and de Greeff S.C. The case for maternal vaccination against pertussis. Lancet Infect. Dis. 7 (2007) 614-624
112. Mooi F.R., He Q., and Guiso N. Phylogeny, evolution, and epidemiology of Bordetellae. In: Locht C. (Ed). Bordetella Molecular Microbiology (2007), Horizon Bioscience, Norfolk, UK 17-45
113. Mooi F.R., He Q., van Oirschot H., and Mertsola J. Variation in the Bordetella pertussis virulence factors pertussis toxin and pertactin in vaccine strains and clinical isolates in Finland. Infect. Immun. 67 (1999) 3133-3134
114. Mooi F.R., van Loo I.H., and King A.J. Adaptation of Bordetella pertussis to vaccination: a cause for its reemergence?. Emerg. Infect. Dis. 7 (2001) 526-528
115. Mooi F.R., van Loo I.H.M., van Gent M., He Q., Heuvelman C.J., Bart M.J., de Greeff S.C., Diavatopoulos D.A., Teunis P.F., Nagelkerke N.J., and Mertsola J. Bordetella pertussis with increased pertussis toxin production associated with pertussis resurgence. Emerg. Infect. Dis. 15 (2009) 1206-1213
116. Mooi F.R., van Oirschot H., Heuvelman K., van der Heide H.G., Gaastra W., and Willems R.J. Polymorphism in the Bordetella pertussis virulence factors P.69/pertactin and pertussis toxin in The Netherlands: temporal trends and evidence for vaccine-driven evolution. Infect. Immun. 66 (1998) 670-675
117. Moran N.A., and Plague G.R. Genomic changes following host restriction in bacteria. Curr. Opin. Genet. Dev. 14 (2004) 627-633
118. Muyldermans G., Hoebrekx N., Soetens O., De Schutter A., Malfroot A., Pierard D., and Lauwers S. Polymorphism of Belgian Bordetella pertussis isolates. J. Microb. Meth. 47 (2001) 108-1108
119. Njamkepo E., Cantinelli T., Guigon G., and Guiso N. Genomic analysis and comparison of Bordetella pertussis isolates circulating in low and high vaccine coverage areas. Microb. Infect. 10 (2008) 1582-1586
120. Njamkepo E., Rimlinger F., Thiberge S., and Guiso N. Thirty-five years' experience with the whole-cell pertussis vaccine in France: vaccine strains analysis and immunogenicity. Vaccine 20 (2002) 1290-1294
121. Orr H.A. The genetic theory of adaptation: a brief history. Nat. Rev. Genet. 6 (2005) 119-127
122. Osborne S.E., Walthers D., Tomljenovic A.M., Mulder D.T., Silphaduang U., Duong N., Lowden M.J., Wickham M.E., Waller R.F., Kenney L.J., and Coombes B.K. Pathogenic adaptation of intracellular bacteria by rewiring a cis-regulatory input function. Proc. Natl. Acad. Sci. U.S.A. 106 (2009) 3982-3987
123. Packard E.R., Parton R., Coote J.G., and Fry N.K. Sequence variation and conservation in virulence-related genes of Bordetella pertussis isolates from the UK. J. Med. Microbiol. 53 (2004) 355-365
124. Parkhill J., Sebaihia M., Preston A., Murphy L.D., Thomson N., Harris D.E., Holden M.T., Churcher C.M., Bentley S.D., Mungall K.L., Cerdeno-Tarraga A.M., Temple L., James K., Harris B., Quail M.A., Achtman M., Atkin R., Baker S., Basham D., Bason N., Cherevach I., Chillingworth T., Collins M., Cronin A., Davis P., Doggett J., Feltwell T., Goble A., Hamlin N., Hauser H., Holroyd S., Jagels K., Leather S., Moule S., Norberczak H., O'Neil S., Ormond D., Price C., Rabbinowitsch E., Rutter S., Sanders M., Saunders D., Seeger K., Sharp S., Simmonds M., Skelton J., Squares R., Squares S., Stevens K., Unwin L., Whitehead S., Barrell B.G., and Maskell D.J. Comparative analysis of the genome sequences of Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica. Nat. Genet. 35 (2003) 32-40
125. Peppler M.S., Kuny S., Nevesinjac A., Rogers C., de Moissac Y.R., Knowles K., Lorange M., De Serres G., and Talbot J. Strain variation among Bordetella pertussis isolates from Quebec and Alberta provinces of Canada from 1985 to 1994. J. Clin. Microbiol. 41 (2003) 3344-3347
126. Peppoloni S., Pizza M., De Magistris M.T., Bartoloni A., and Rappuoli R. Acellular pertussis vaccine composed of genetically inactivated pertussis toxin. Physiol. Chem. Phys. Med. NMR 27 (1995) 355-361
127. Perez J.C., and Groisman E.A. Transcription factor function and promoter architecture govern the evolution of bacterial regulons. Proc. Natl. Acad. Sci. U.S.A. 106 (2009) 4319-4324
128. Pierce C., Klein N., and Peters M. Is leukocytosis a predictor of mortality in severe pertussis infection?. Intensive Care Med. 26 (2000) 1512-1514
129. Porter J.F., Connor K., and Donachie W. Differentiation between human and ovine isolates of Bordetella parapertussis using pulsed-field gel electrophoresis. FEMS Microbiol. Lett. 135 (1996) 131-135
130. Poynten M., McIntyre P.B., Mooi F.R., Heuvelman K.J., and Gilbert G.L. Temporal trends in circulating Bordetella pertussis strains in Australia. Epidemiol. Infect. 132 (2004) 185-193
131. Preston N.W. Essential immunogens in human pertussis: the role of fimbriae. Dev. Biol. Stand. 61 (1985) 137-141
132. Preziosi M.P., Yam A., Wassilak S.G., Chabirand L., Simaga A., Ndiaye M., Dia M., Dabis F., and Simondon F. Epidemiology of pertussis in a West African community before and after introduction of a widespread vaccination program. Am. J. Epidemiol. 155 (2002) 891-896
133. Riboli B., Pedroni P., Cuzzoni A., Grandi G., and de F.F. Expression of Bordetella pertussis fimbrial (fim) genes in Bordetella bronchiseptica: fimX is expressed at a low level and vir-regulated. Microb. Pathog. 10 (1991) 393-403
134. Roush S.W., and Murphy T.V. Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. J. Am. Med. Assoc. 298 (2007) 2155-2163
135. Ryan M., Murphy G., Ryan E., Nilsson L., Shackley F., Gothefors L., Oymar K., Miller E., Storsaeter J., and Mills K.H. Distinct T-cell subtypes induced with whole cell and acellular pertussis vaccines in children. Immunology 93 (1998) 1-10
136. Sako W. Studies on pertussis immunization. J. Pediatr. 30 (1947) 29-40
137. Schouls L., van der H.H., Witteveen S., Zomer B., van der E.A., Burger M., and Schot C. Two variants among Haemophilus influenzae serotype b strains with distinct bcs4, hcsA and hcsB genes display differences in expression of the polysaccharide capsule. BMC Microbiol. 8 (2008) 35
138. Schouls L.M., van der Heide H.G., Vauterin L., Vauterin P., and Mooi F.R. Multiple-locus variable-number tandem repeat analysis of Dutch Bordetella pertussis strains reveals rapid genetic changes with clonal expansion during the late 1990s. J. Bacteriol. 186 (2004) 5496-5505
139. Smith N.H., Hewinson R.G., Kremer K., Brosch R., and Gordon S.V. Myths and misconceptions: the origin and evolution of Mycobacterium tuberculosis. Nat. Rev. Microbiol. 7 (2009) 537-544
140. Soto C.Y., Menendez M.C., Perez E., Samper S., Gomez A.B., Garcia M.J., and Martin C. IS6110 mediates increased transcription of the phoP virulence gene in a multidrug-resistant clinical isolate responsible for tuberculosis outbreaks. J. Clin. Microbiol. 42 (2004) 212-219
141. Stefanelli P., Fazio C., Fedele G., Spensieri F., Ausiello C.M., and Mastrantonio P. A natural pertactin deficient strain of Bordetella pertussis shows improved entry in human monocyte-derived dendritic cells. New Microbiol. 32 (2009) 159-166
142. Stibitz S., Aaronson W., Monack D., and Falkow S. Phase variation in Bordetella pertussis by frameshift mutation in a gene for a novel two-component system. Nature 338 (1989) 266-269
143. Stibitz S. The bvg regulon. In: Locht C. (Ed). Bordetella Molecular Microbiology (2007), Horizon Bioscience, Norfolk, UK 47-67
144. Stibitz S., and Yang M.S. Genomic fluidity of Bordetella pertussis assessed by a new method for chromosomal mapping. J. Bacteriol. 179 (1997) 5820-5826
145. Still G.F. The History of Paediatrics (1931), Oxford University Press, London
146. Storsaeter J., Hallander H.O., Gustafsson L., and Olin P. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 16 (1998) 1907-1916
147. Streefland M., van de Waterbeemd B., Happe H., van der Pol L.A., Beuvery E.C., et al. PAT for vaccines: the first stage of PAT implementation for development of a well-defined whole-cell vaccine against whooping cough disease. Vaccine 25 (2007) 2994-3000
148. Streisinger G., and Owen J. Mechanisms of spontaneous and induced frameshift mutation in bacteriophage T4. Genetics 109 (1985) 633-659
149. Taranger J., Trollfors B., Bergfors E., Knutsson N., Sundh V., Lagergard T., Lind-Brandberg L., Zackrisson G., White J., Cicirello H., Fusco J., and Robbins J.B. Mass vaccination of children with pertussis toxoid - decreased incidence in both vaccinated and nonvaccinated persons. Clin. Infect. Dis. 33 (2001) 1004-1010
150. Taranger J., Trollfors B., Lagergard T., Sundh V., Bryla D.A., Schneerson R., and Robbins J.B. Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis. J. Infect. Dis. 181 (2000) 1010-1013
151. Tsang R.S., Lau A.K., Sill M.L., Halperin S.A., Van Caeseele P., Jamieson F., and Martin I.E. Polymorphisms of the fimbria fim3 gene of Bordetella pertussis strains isolated in Canada. J. Clin. Microbiol. 42 (2004) 5364-5367
152. Tsang R.S., Sill M.L., Martin I.E., and Jamieson F. Genetic and antigenic analysis of Bordetella pertussis isolates recovered from clinical cases in Ontario, Canada, before and after the introduction of the acellular pertussis vaccine. Can. J. Microbiol. 51 (2005) 887-892
153. Uria M.J., Zhang Q., Li Y., Chan A., Exley R.M., Gollan B., Chan H., Feavers I., Yarwood A., Abad R., Borrow R., Fleck R.A., Mulloy B., Vazquez J.A., and Tang C.M. A generic mechanism in Neisseria meningitidis for enhanced resistance against bactericidal antibodies. J. Exp. Med. 205 (2008) 1423-1434
154. van Amersfoorth S.C., Schouls L.M., van der Heide H.G., Advani A., Hallander H.O., Bondeson K., vonKonig C.H.W., Riffelmann M., Vahrenholz C., Guiso N., Caro V., Njamkepo E., He Q., Mertsola J., and Mooi F.R. Analysis of Bordetella pertussis populations in European countries with different vaccination policies. J. Clin. Microbiol. 43 (2005) 2837-2843
155. Vandebriel R.J., Hellwig S.M., Vermeulen J.P., Hoekman J.H., Dormans J.A., Roholl P.J., and Mooi F.R. Association of Bordetella pertussis with host immune cells in the mouse lung. Microb. Pathog. 35 (2003) 19-29
156. van der Zee A., Groenendijk H., Peeters M., and Mooi F.R. The differentiation of Bordetella parapertussis and Bordetella bronchiseptica from humans and animals as determined by DNA polymorphism mediated by two different insertion sequence elements suggests their phylogenetic relationship. Int. J. Syst. Bacteriol. 46 (1996) 640-647
157. van der Zee A., Mooi F., Van Embden J., and Musser J. Molecular evolution and host adaptation of Bordetella spp.: phylogenetic analysis using multilocus enzyme electrophoresis and typing with three insertion sequences. J. Bacteriol. 179 (1997) 6609-6617
158. van Gent M., de Greeff S.C., van der Heide H.G., and Mooi F.R. An investigation into the cause of the 1983 whooping cough epidemic in the Netherlands. Vaccine 27 (2009) 1898-1903
159. van Gent M., Pierard D., Lauwers S., van der Heide H.G., King A.J., and Mooi F.R. Characterization of Bordetella pertussis clinical isolates that do not express the tracheal colonization factor. FEMS Immunol. Med. Microbiol. 51 (2007) 149-154
160. van Loo I.H., Heuvelman K.J., King A.J., and Mooi F.R. Multilocus sequence typing of Bordetella pertussis based on surface protein genes. J. Clin. Microbiol. 40 (2002) 1994-2001
161. van Loo I.H., and Mooi F.R. Changes in the Dutch Bordetella pertussis population in the first 20 years after the introduction of whole-cell vaccines. Microbiology 148 (2002) 2011-2018
162. van Loo I.H., van der Heide H.G., Nagelkerke N.J., Verhoef J., and Mooi F.R. Temporal trends in the population structure of Bordetella pertussis during 1949-1996 in a highly vaccinated population. J. Infect. Dis. 179 (1999) 915-923
163. Ward J.I., Cherry J.D., Chang S.J., Partridge S., Keitel W., Edwards K., Lee M., Treanor J., Greenberg D.P., Barenkamp S., Bernstein D.I., and Edelman R. Bordetella pertussis infections in vaccinated and unvaccinated adolescents and adults, as assessed in a national prospective randomized Acellular Pertussis Vaccine Trial (APERT). Clin. Infect. Dis. 43 (2006) 151-157
164. Warny M., Pepin J., Fang A., Killgore G., Thompson A., Brazier J., Frost E., and McDonald L.C. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 366 (2005) 1079-1084
165. Watanabe M., and Nagai M. Effect of acellular pertussis vaccine against various strains of Bordetella pertussis in a murine model of respiratory infection. J. Health Sci. 48 (2002) 560-564
166. Watanabe M., and Nagai M. Whooping cough due to Bordetella parapertussis: an unresolved problem. Expert Rev. Anti-Infect. Ther. 2 (2004) 447-454
167. Weber C., Boursaux-Eude C., Coralie G., Caro V., and Guiso N. Polymorphism of Bordetella pertussis isolates circulating for the last 10 years in France, where a single effective whole-cell vaccine has been used for more than 30 years. J. Clin. Microbiol. 39 (2001) 4396-4403
168. WHO. Challenges in global immunization and the Global Immunization Vision and Strategy 2006-2015. Weekly Epidemiol. Rec. 81 (2006) 190-195
169. Willems R., Paul A., van der Heide H.G., ter Avest A.R., and Mooi F.R. Fimbrial phase variation in Bordetella pertussis: a novel mechanism for transcriptional regulation. EMBO J. 9 (1990) 2803-2809
170. Winfield M.D., and Groisman E.A. Phenotypic differences between Salmonella and Escherichia coli resulting from the disparate regulation of homologous genes. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 17162-17167
171. Wisniewski-Dye F., and Vial L. Phase and antigenic variation mediated by genome modifications. A. v. Leeuw. 94 (2008) 493-515
172. Wright G.D. The antibiotic resistome: the nexus of chemical and genetic diversity. Nat. Rev. Microbiol. 5 (2007) 175-186
173. Yao S.M., Lin Y.C., Chou C.Y., Chen Y.Y., Hsiao M.J., Chen H.Y., Yan J.J., Su H.P., and Li S.Y. Antigenic divergence of Bordetella pertussis isolates in Taiwan. J. Clin. Microbiol. 43 (2005) 5457-5461